Kynurenine 3-monooxygenase polymorphisms: relevance for kynurenic acid synthesis in patients with schizophrenia and healthy controls

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Kynurenine 3-monooxygenase polymorphisms: relevance for kynurenic acid synthesis in patients with schizophrenia and healthy controls. / Holtze, Maria; Saetre, Peter; Engberg, Göran; Schwieler, Lilly; Werge, Thomas; Andreassen, Ole A; Hall, Håkan; Terenius, Lars; Agartz, Ingrid; Jönsson, Erik G; Schalling, Martin; Erhardt, Sophie.

I: Journal of Psychiatry and Neuroscience, Bind 37, Nr. 1, 2012, s. 53-7.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Holtze, M, Saetre, P, Engberg, G, Schwieler, L, Werge, T, Andreassen, OA, Hall, H, Terenius, L, Agartz, I, Jönsson, EG, Schalling, M & Erhardt, S 2012, 'Kynurenine 3-monooxygenase polymorphisms: relevance for kynurenic acid synthesis in patients with schizophrenia and healthy controls', Journal of Psychiatry and Neuroscience, bind 37, nr. 1, s. 53-7. https://doi.org/10.1503/jpn.100175

APA

Holtze, M., Saetre, P., Engberg, G., Schwieler, L., Werge, T., Andreassen, O. A., Hall, H., Terenius, L., Agartz, I., Jönsson, E. G., Schalling, M., & Erhardt, S. (2012). Kynurenine 3-monooxygenase polymorphisms: relevance for kynurenic acid synthesis in patients with schizophrenia and healthy controls. Journal of Psychiatry and Neuroscience, 37(1), 53-7. https://doi.org/10.1503/jpn.100175

Vancouver

Holtze M, Saetre P, Engberg G, Schwieler L, Werge T, Andreassen OA o.a. Kynurenine 3-monooxygenase polymorphisms: relevance for kynurenic acid synthesis in patients with schizophrenia and healthy controls. Journal of Psychiatry and Neuroscience. 2012;37(1):53-7. https://doi.org/10.1503/jpn.100175

Author

Holtze, Maria ; Saetre, Peter ; Engberg, Göran ; Schwieler, Lilly ; Werge, Thomas ; Andreassen, Ole A ; Hall, Håkan ; Terenius, Lars ; Agartz, Ingrid ; Jönsson, Erik G ; Schalling, Martin ; Erhardt, Sophie. / Kynurenine 3-monooxygenase polymorphisms: relevance for kynurenic acid synthesis in patients with schizophrenia and healthy controls. I: Journal of Psychiatry and Neuroscience. 2012 ; Bind 37, Nr. 1. s. 53-7.

Bibtex

@article{f603560b8a184715aae65fa9a8130b9a,
title = "Kynurenine 3-monooxygenase polymorphisms: relevance for kynurenic acid synthesis in patients with schizophrenia and healthy controls",
abstract = "Background: Patients with schizophrenia show increased brain and cerebrospinal fluid (CSF) concentrations of the endogenous N-methyl-D-aspartate receptor antagonist kynurenic acid (KYNA). This compound is an end-metabolite of the kynurenine pathway, and its formation indirectly depends on the activity of kynurenine 3-monooxygenase (KMO), the enzyme converting kynurenine to 3-hydroxykynurenine. Methods: We analyzed the association between KMO gene polymorphisms and CSF concentrations of KYNA in patients with schizophrenia and healthy controls. Fifteen single nucleotide polymorphisms (SNPs) were selected covering KMO and were analyzed in UNPHASED. Results: We included 17 patients with schizophrenia and 33 controls in our study. We found an association between a KMO SNP (rs1053230), encoding an amino acid change of potential importance for substrate interaction, and CSF concentrations of KYNA. Limitations: Given the limited sample size, the results are tentative until replication. Conclusion: Our results suggest that the nonsynonymous KMO SNP rs1053230 influences CSF concentrations of KYNA.",
author = "Maria Holtze and Peter Saetre and G{\"o}ran Engberg and Lilly Schwieler and Thomas Werge and Andreassen, {Ole A} and H{\aa}kan Hall and Lars Terenius and Ingrid Agartz and J{\"o}nsson, {Erik G} and Martin Schalling and Sophie Erhardt",
year = "2012",
doi = "10.1503/jpn.100175",
language = "English",
volume = "37",
pages = "53--7",
journal = "Journal of Psychiatry and Neuroscience",
issn = "1180-4882",
publisher = "Canadian Medical Association",
number = "1",

}

RIS

TY - JOUR

T1 - Kynurenine 3-monooxygenase polymorphisms: relevance for kynurenic acid synthesis in patients with schizophrenia and healthy controls

AU - Holtze, Maria

AU - Saetre, Peter

AU - Engberg, Göran

AU - Schwieler, Lilly

AU - Werge, Thomas

AU - Andreassen, Ole A

AU - Hall, Håkan

AU - Terenius, Lars

AU - Agartz, Ingrid

AU - Jönsson, Erik G

AU - Schalling, Martin

AU - Erhardt, Sophie

PY - 2012

Y1 - 2012

N2 - Background: Patients with schizophrenia show increased brain and cerebrospinal fluid (CSF) concentrations of the endogenous N-methyl-D-aspartate receptor antagonist kynurenic acid (KYNA). This compound is an end-metabolite of the kynurenine pathway, and its formation indirectly depends on the activity of kynurenine 3-monooxygenase (KMO), the enzyme converting kynurenine to 3-hydroxykynurenine. Methods: We analyzed the association between KMO gene polymorphisms and CSF concentrations of KYNA in patients with schizophrenia and healthy controls. Fifteen single nucleotide polymorphisms (SNPs) were selected covering KMO and were analyzed in UNPHASED. Results: We included 17 patients with schizophrenia and 33 controls in our study. We found an association between a KMO SNP (rs1053230), encoding an amino acid change of potential importance for substrate interaction, and CSF concentrations of KYNA. Limitations: Given the limited sample size, the results are tentative until replication. Conclusion: Our results suggest that the nonsynonymous KMO SNP rs1053230 influences CSF concentrations of KYNA.

AB - Background: Patients with schizophrenia show increased brain and cerebrospinal fluid (CSF) concentrations of the endogenous N-methyl-D-aspartate receptor antagonist kynurenic acid (KYNA). This compound is an end-metabolite of the kynurenine pathway, and its formation indirectly depends on the activity of kynurenine 3-monooxygenase (KMO), the enzyme converting kynurenine to 3-hydroxykynurenine. Methods: We analyzed the association between KMO gene polymorphisms and CSF concentrations of KYNA in patients with schizophrenia and healthy controls. Fifteen single nucleotide polymorphisms (SNPs) were selected covering KMO and were analyzed in UNPHASED. Results: We included 17 patients with schizophrenia and 33 controls in our study. We found an association between a KMO SNP (rs1053230), encoding an amino acid change of potential importance for substrate interaction, and CSF concentrations of KYNA. Limitations: Given the limited sample size, the results are tentative until replication. Conclusion: Our results suggest that the nonsynonymous KMO SNP rs1053230 influences CSF concentrations of KYNA.

U2 - 10.1503/jpn.100175

DO - 10.1503/jpn.100175

M3 - Journal article

C2 - 21693093

VL - 37

SP - 53

EP - 57

JO - Journal of Psychiatry and Neuroscience

JF - Journal of Psychiatry and Neuroscience

SN - 1180-4882

IS - 1

ER -

ID: 40205042